New study demonstrates efficacy of all-oral treatment regimens in adolescents with hepatitis C virus

Adolescents with Hepatitis C (HCV) could benefit from a combination of direct-acting antivirals, according to new data. The study demonstrated that adolescent patients with HCV genotype 1 aged 12 to 18 years who were treated for 12 weeks with a fixed dose combination of ledipasvir and sofosbuvir attained high sustained virologic response (SVR) rates.